Oyster Point Pharma downgraded by JP Morgan with a new price target

11/9/21 4:30:34 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

JP Morgan downgraded Oyster Point Pharma from Overweight to Neutral and set a new price target of $23.00 from $30.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OYST

Date	Price Target	Rating	Analyst
8/11/2022	$22.00	Buy	Chardan Capital Markets
7/18/2022	$20.00	Buy	H.C. Wainwright
11/9/2021	$30.00 → $23.00	Overweight → Neutral	JP Morgan